Latest Updates of Companies in the U.S. Non-Invasive Cancer Diagnostics Market
| Company | Headquarters | Latest Update |
| Illumina, Inc. | United States | This company leader in DNA sequencing and array-based technologies. Their platforms are foundational for detecting genetic mutations linked to cancer. |
| Exact Sciences Corporation | United States | Pioneers in non-invasive colorectal cancer screenings, a standard known for its stool-DNA test. |
| Guardant Health, Inc. | United States | Precision oncology leader specializing in liquid biopsies and inclusive genomic profiling. |
| F. Hoffmann-La Roche Ltd | United States | This product provides a comprehensive portfolio of cancer tissue diagnostics and molecular testing solutions. |
Recent Developments in the U.S. Non-Invasive Cancer Diagnostics Market
- In April 2026, Guardant Health, Inc. announced a multi-year strategic partnership with Nuvalent, Inc. to support the development and potential commercialization of Nuvalent’s oncology pipeline using the tissue and liquid offerings of the Guardant Infinity platform.
- In March 2026, Illumina, Inc. and Labcorp, a worldwide leader of innovative and comprehensive laboratory services, announced an expanded collaboration to advance precision oncology through innovative applications of next-generation sequencing (NGS) services across the healthcare ecosystem.
- In December 2025, the Hackensack Meridian Hennessy Institute for Cancer Prevention and Applied Molecular Medicine announced an advanced collaboration with DELFI Diagnostics, supported by a Healthcare Improvement grant from Lilly to enhance lung-cancer screening adherence.
- In November 2025, Oasis Diagnostics Corporation and UCM Technologies Announce Partnership to Enable At-Home Saliva Collection for Next-Generation Cancer Screening Test
Supply Chain Analysis
R&D
- Research and development in non-invasive cancer diagnostics focuses on biomarker discovery, liquid biopsy technologies, artificial intelligence integration, genomic sequencing, and assay optimization to improve early detection, accuracy, and oncology applications.
- Guardant Health, Illumina, Exact Sciences, Freenome, GRAIL, Natera, Bio-Rad Laboratories.
Clinical Trials & Regulatory Approvals
- Clinical trials and regulatory approvals validate non-invasive cancer diagnostic technologies through performance evaluations, patient studies, compliance documentation, and regulatory submissions, ensuring safety, reliability, commercialization readiness, and broader healthcare adoption globally.
- Roche, Thermo Fisher Scientific, Qiagen, Guardant Health, GRAIL, Exact Sciences, Foundation Medicine.
Market Growth
The U.S. non-invasive cancer diagnostics market size was estimated at USD 38.42 billion in 2025 and is predicted to increase from USD 42.58 billion in 2026 to approximately USD 107.53 billion by 2035, expanding at a CAGR of 10.84% from 2026 to 2035.
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking